Jonathan Kay to Certolizumab Pegol
This is a "connection" page, showing publications Jonathan Kay has written about Certolizumab Pegol.
Connection Strength
0.165
-
Deodhar A, Gensler LS, Kay J, Maksymowych WP, Haroon N, Landew? R, Rudwaleit M, Hall S, Bauer L, Hoepken B, de Peyrecave N, Kilgallen B, van der Heijde D. A Fifty-Two-Week, Randomized, Placebo-Controlled Trial of Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol. 2019 07; 71(7):1101-1111.
Score: 0.165